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Abstract
Introduction: The role of positron emission tomography
(PET) with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) is
currently under evaluation in urologic oncology. The aim
of the present study was to investigate the use of
[18F]FDG positron emission tomography ([18F]FDG-PET)
in the detection and treatment control of malignant germ
cell tumors compared to computed tomography (CT).
Materials and Methods: Thirty-two PET studies and CT
scans were carried out in 23 patients with histologically
proven germ cell tumors (10 seminomas, 12 non-semi-
nomatous germ cell tumors (NSGCT), 1 unclassified
serologic recurrent disease) Lugano stage I–III. The scans
were done either after initial diagnosis (n = 21) and/or
within 3–45 days after chemotherapy was completed (n =
11). PET and CT were validated either by histology (n = 7)
or clinical follow-up of 6–11 months after the last PET
study has been performed (n = 16). Sensitivity, specifici-
ty, accuracy, positive and negative predictive values
were determined for PET and CT. Differences between
PET and CT for parameters of diagnostic value were eval-
uated by ̄ 2 test. Results: Although not statistically signif-
icant, the sensitivity, accuracy and negative predictive
value were higher for PET than for CT with respect to the
detection of metastatic infradiaphragmatic and supra-
diaphragmatic lesions after initial diagnosis. The speci-
ficity and positive predictive value of PET and CT were
comparable. After chemotherapy, PET was found to be
significantly superior in specificity and accuracy com-
pared to CT with respect to infradiaphragmatic lesions
(p ! 0.05). False-positive PET findings in supradiaphrag-
matic lesions after chemotherapy occurred in the case of
inflammatory processes and resulted in a loss of speci-
ficity and accuracy compared to CT (p ! 0.05). Conclu-
sions: These preliminary results demonstrate [18F]FDG-
PET to be a useful diagnostic tool for the initial staging
and treatment control in patients with germ cell tumors.
Possible advantages compared to CT, however, are as
yet not clearly defined. The possibility of false-positive
PET findings due to reactive supradiaphragmatic inflam-
matory processes early after chemotherapy have to be
considered.
Copyright © 2002 S. Karger AG, Basel
158 Urol Int 2002;68:157–163 Tsatalpas et al.
Introduction
The role of positron emission tomography (PET) with
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) is currently
under evaluation in urologic oncology [1–9]. Recent stud-
ies have shown that the uptake of [18F]FDG is increased
in many tumor entities compared to normal tissue [10,
11]. Effective chemotherapy has been found to reduce the
[18F]FDG uptake prior to volumetric changes in morpho-
logical imaging techniques such as computed tomography
(CT) [12–14]. In this study, the potential of [18F]FDG-
PET for the detection and treatment assessment of testic-
ular germ cell tumors was investigated.
Malignant germ cell tumors are histologically catego-
rized into seminomas (40%) and into the heterogeneous
group of non-seminomatous germ cell tumors (60%) com-
prising embryonal carcinoma, chorionic carcinoma, ma-
lignant teratoma, yolk sac tumor and mixed or combined
tumors [15].
With the introduction of cis-platinum-based polyche-
motherapy, the prognosis of metastatic testicular cancer
has been improved dramatically and therefore germ cell
tumors are today eminently curable. Cure rates of 80–
90% were reported in Lugano stage II–III patients and
cure is also possible in patients who failed to achieve com-
plete remission after initial therapy [16].
Staging after the initial diagnosis and the response of
metastatic testicular cancer to chemotherapy is usually
undertaken by computed tomography (CT) and by mea-
suring the serum levels of two well-established tumor
markers, ß-human chorionic gonadotropin (ß-HCG) and
·-fetoprotein (AFP). However, CT-based clinical staging
has been shown to have a false-negative rate in clinical
stage I patients of 30–40% [17]. Also, about 40% of malig-
nant testicular germ cell tumors cannot be monitored
using the tumor markers mentioned above. After chemo-
therapy, almost 30% of the patients still have residual
tumors on CT scanning which is unable to differentiate
between vital tumor masses and residual scar tissue.
Often surgery and histopathological analysis are needed
to define the nature of a residual tumor mass after chemo-
therapy.
Due to the excellent contemporary cure rates of testic-
ular cancer, the treatment-induced morbidity of chemo-
therapy and/or surgery for metastatic disease has become
an important issue. Therefore, new diagnostic tools are
needed to enhance the diagnostic accuracy of staging and
treatment control of malignant germ cell tumors.
Material and Methods
Patients
Twenty-three patients with histopathologically proven testicular
germ cell tumors were included. The histological diagnosis was semi-
noma in 10 patients (43.4%), a combined tumor in 9 (39.1%),
embryonal carcinoma in 3 (13.1%), and 1 patient (4.4%) had an
unclassified serologic recurrent disease (AFP: 631 ng/ml) of a com-
bined testicular tumor 2 years after initial orchiectomy. Tumor stag-
ing was assessed according to classification of the international work-
shop on staging and treatment of testicular cancer in Lugano [18].
The final diagnosis was stage I in 11 (47.8%), stage II in 6 (26.1%),
and stage III in 6 patients (26.1%). Sixteen patients received chemo-
therapy (5 of them adjuvant only) and 6 patients underwent retro-
peritoneal lymphadenectomy (RLA) (3 primary RLA and 3 salvage
RLA). One patient received high-dose salvage PEI chemotherapy
with autologous bone marrow support after initial PEB chemothera-
py and 1 patient underwent mediastinal lymph node dissection with
resection of a pulmonary residual tumor mass after chemotherapy.
4/7 patients with a stage I seminoma received an adjuvant radiation
therapy (26 Gy), 2 an adjuvant monochemotherapy with 2 series of
carboplatine and 1 patient who refused any adjuvant treatment was
put on a surveillance program.
A total of 32 PET scans were carried out. The scans were done
either after initial diagnosis (n = 21) and/or within 3–45 days after
chemotherapy was completed (stage II–III patients only, n = 11). CT
scanning was done within 24 h of PET scanning in all patients.
PET Imaging
PET studies were performed after patients had fasted for 6–12 h.
Plasma glucose levels at the time of [18F]FDG injection were within
physiological limits. Patients with diabetes mellitus were not in-
cluded in the present study. [18F]FDG was provided by the Institute
of Bioanorganic and Radiopharmaceutical Chemistry, Research
Center Rossendorf, Germany. Patients received 185–390 MBq
[18F]FDG by intravenous injection.
Fifteen of the 21 initial PET scans and all eleven PET scans after
chemotherapy were carried out using an ECAT EXACT HR+ PET
scanner (Siemens/CTI, Knoxville, Tenn., USA). Technical data: field
of view: 15.2 cm; 63 cm contiguous cross-sectional slices per bed
position with a slice thickness of 2.4 m in-plane resolution of 4–5 mm
FWHM (full-width half-maximum). Image reconstruction was done
using filtered backprojection with a 128 ! 128 matrix size. Emission
scans of the abdomen were corrected for photon attenuation by mea-
sured transmission scans using a retractable 68Ge ring source. Acqui-
sition of emission data started 60 min after intravenous injection of
266–390 MBq [18F]FDG and lasted for 50–60 min.
Six of the 21 initial [18F]FDG scans were done using a dual head
coincidence gamma camera (Solus EPIC MCD, ADAC Laboratories,
Milpitas, Calif., USA). This camera covers a field of view of
38 cm. Two to three scans overlapping 35% were acquired in 3D
mode with 32 angles of 40 s each. Reconstruction was performed
with an iterative method implemented by the manufacturer (4 itera-
tions, 8 ordered subsets). In-plane resolution of the device was
around 4 mm FWHM (full-width half-maximum). Acquisition of
emission data was started 60 min after intravenous injection of 100–
140 MBq and lasted for 60–90 min.
The visual analysis was graded as clearly positive when high
[18F]FDG uptake was seen as a hot spot, or suspected when slightly
enhanced accumulation of [18F]FDG compared with the expected
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normal distribution in the surrounding region was detected. Other-
wise, the image was interpreted as negative for malignancy. The
interpretation of PET scans was done by nuclear medicine specialists
without knowledge of CT results.
In studies performed with the dedicated PET scanner quantita-
tive image analysis of tumor uptake was performed by calculating the
standardized uptake values (SUVs) in selected regions of interest
(ROI) according to the formula [19]:
SUV = 
Radioactivity concentration in ROI [Bq/g] ! patient’s weight [g]
injected dose [Bq]
CT Imaging
34 CT scans (23 initial and 11 after chemotherapy) were done
corresponding to all PET studies. CT scans were obtained with third-
or fourth- generation CT scanners by the Department of Radiology of
the University of Dresden. Transverse cross sections of 10 mm slice
thickness were used. Oral and intravenous contrast medium was
applied for all abdominal scans. Intravenous contrast medium was
given for all thoracic CT scans. CT scans for initial staging were inter-
preted as suspicious for metastatic lymphatic spread, if the lymph
node was bigger than 1.5 cm and for organ metastases, if characteris-
tic radiological signs like contrast enhancement after intravenous
contrast medium application was seen. The CT images were exam-
ined by radiologists without knowledge of the PET results.
Tumor Markers
Tumor marker levels of AFP and ß-HCG were available for all
patients. AFP 19 ng/ml and ß-HCG 15 U/l were considered patho-
logic.
Validation and Statistics
Validation was done either by histology (n = 7) or by clinical fol-
low-up of 6–11 months after the last PET study had been done (n =
16). Absence of disease after therapy was assumed, if patients were
without signs of progression on CT, and tumor markers were nega-
tive for at least 6 months without further treatment. Tissue for histol-
ogy was obtained by retroperitoneal lymphadenectomy (n = 6) and
thoracotomy (n = 1).
Sensitivity, specificity, positive and negative predictive values
and accuracy were determined for both PET and CT. Differences
between PET and CT for these parameters of diagnostic value were
evaluated by chi-square test. The accepted limit to indicate statistical
significance was p ! 0.05. All statistical tests were calculated with the
MEDAS statistical software package for PC (Grund, Würzburg, Ger-
many).
Results
Accumulation of [18F]FDG was detected in 9 of 21
(42.8%) of the primary PET studies by visual analysis.
Eight were graded as clearly positive (++) and one as sus-
pect (+). All lesions with primarily clearly positive visual
findings represent metastatic lesions proven either by his-
tology or clinical follow-up. The one PET study graded as
suspect showed multiple retroperitoneal and mediastinal
lesions with SUV values between 2.6 and 4.0. The corre-
sponding CT in that case (primary histology: teratoma
and embryonal carcinoma) showed multiple retroperito-
neal, lung and mediastinal metastases, the largest measur-
ing 9.2 ! 8.6 ! 15 cm. In another case in which the CT
scan suggested two metastatic lesions, a retroperitoneal
and a parailiacal one, PET identified only the retroperito-
neal one, but not the parailiacal lesion. The correct PET
staging was proven by retroperitoneal and parailiacal
lymphadenectomy, where the parailiacal lesion was veri-
fied to be an ectopic seminal vesicle. One patient showed
two clearly positive retroperitoneal lesions with SUV val-
ues of 6.0 in the typical location which CT failed to identi-
fy. These lesions disappeared after 3 series of cisplatinum-
based chemotherapy. In 1 patient PET scanning identi-
fied a clearly positive mediastinal metastatic lesion in
contrast to CT findings, which disappeared after two
series of cisplatinum-based chemotherapy. In another pa-
tient, control CT two years after orchiectomy also failed
to identify metastases in spite of serologic AFP levels of
631 ng/ml. In contrast to CT, PET showed one lung and
multiple mediastinal lesions.
Twelve of 21 primary PET studies (57.2%) were
graded as negative in agreement with clinical and CT
findings. In one of these cases (primary histology: em-
bryonal carcinoma with seminoma) retroperitoneal
lymphadenectomy identified one solitary lymph node
metastasis with a histology similar to the primary tumor.
Statistical analysis of the initial findings (see also
table 1) showed PET to be more sensitive (0.90 vs. 0.60),
accurate (0.95 vs. 0.81) and to have a higher negative pre-
dictive value (0.92 vs. 0.73) than CT, but these differences
were not statistically significant, although the specificity
and positive predictive value were in the same range as
that of CT.
The PET scans after the completion of chemotherapy
showed accumulation of [18F]FDG in 5 of 11 cases
(45.45%). The lesions seen in the control PET were in one
of these cases in the same locations as in the primary PET
and were proven to be metastases. In the other 4 cases,
those lesions found to be positive in the control PET were
in different locations (lung and neck) compared to the
findings in the first PET scan while the primary lesions
had disappeared completely. Histology after thoracotomy
(1 of 4 cases), antibiotic treatment and clinical follow-up
(3 of 4 cases) showed that these lesions were of an inflam-
matory nature.
6/11 (54.55%) PET scans after chemotherapy showed
no accumulation of [18F]FDG. In 4 of these 6 patients CT
W-PET
W-PET
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Table 1. Primary diagnostic value of
PET vs. CT (n = 21) Primary TP FN TN FP SENS SPEC ACC PPV NPV
9 of 10 1 of 10 11 of 11 0 of 11 0.90 1.0 0.95 1.0 0.92
W-CT 6 of 10 4 of 10 11 of 11 0 of 11 0.60 1.0 0.81 1.0 0.73
I-PET 6 of 7 1 of 7 14 of 14 0 of 14 0.85 1.0 0.95 1.0 0.93
I-CT 5 of 7 2 of 7 14 of 14 0 of 14 0.71 1.0 0.91 1.0 0.87
S-PET 4 of 5 1 of 5 16 of 16 0 of 16 0.80 1.0 0.95 1.0 0.94
S-CT 3 of 5 2 of 5 16 of 16 0 of 16 0.60 1.0 0.90 1.0 0.89
¯2 test: p 60.05 (not significant) in all possible combinations (vertical reading).
W = Whole body; I = infradiaphragmatic; S = supradiaphragmatic; TP = true positive;
FN = false negative; TN = true negative; FP = false positive; SENS = sensitivity; SPEC =
specificity; ACC = accuracy; PPV = positive predictive value; NPV = negative predictive
value.
Only patients with primary PET and CT scans were included in this table (n = 21).
Table 2. Diagnostic value of PET versus
CT after chemotherapy Primary TP FN TN FP SENS SPEC ACC PPV NPV
1 of 1 0 of 1 6 of 10 4 of 10 1.0 0.06 0.64 0.20 1.0
W-CT 1 of 1 0 of 1 6 of 10 4 of 10 1.0 0.60 0.64 0.20 1.0
I-PET 1 of 1 0 of 1 10 of 10 0 of 10 1.0 1.0* 1.0* 1.0 1.0
I-CT 1 of 1 0 of 1 6 of 10 4 of 10 1.0 0.60* 0.64* 0.20 1.0
S-PET 1 of 1 0 of 1 6 of 10 4 of 10 1.0 0.60* 0.64* 0.20 1.0
S-CT 1 of 1 0 of 1 10 of 10 0 of 10 1.0 1.0* 1.0* 1.0 1.0
* p ! 0.05 (vertical reading).
W = Whole body; I = infradiaphragmatic; S = supradiaphragmatic; TP = true positive;
FN = false negative; TN = true negative; FP = false positive; SENS = sensitivity; SPEC =
specificity; ACC = accuracy; PPV = positive predictive value; NPV = negative predictive
value.
identified residual tumor masses. After retroperitoneal
lymphadenectomy in three cases, these masses were
shown by histology to be scar tissue and an ectopic semi-
nal vesicle without vital tumor cells. One case with a
residual retroperitoneal tumor mass (2.8 ! 1.0 cm in CT;
primary histology: seminoma) is still without progression
after 8 months. The other 2 patients with negative PET
scans after chemotherapy showed also a complete remis-
sion with respect to control CT and serologic tumor mark-
ers. They are still in remission after a follow-up period of 8
to 11 months.
The statistical analysis of the findings after chemother-
apy (table 2) showed no significant differences between
PET and CT values with respect to whole body detection.
When PET was compared to CT with respect to infra-
diaphragmatic lesions only, PET was shown to be superi-
or in specificity (1.0 vs. 0.60), accuracy (1.0 vs. 0.64) and
positive predictive value (1.0 vs. 0.20). However, signifi-
cant differences between PET and CT were achieved only
for specificity and accuracy (p ! 0.05), but not for the pos-
itive predictive value, although sensitivity and negative
predictive value were in the same range as that of CT.
Only in the case of supradiaphragmatic lesions was CT
shown to be more specific (1.0 vs. 0.60), accurate (1.0 vs.
0.64) and to have higher positive predictive value (1.0 vs.
0.20) compared to PET. Statistical significance was seen
only for the specificity (p ! 0.05) and accuracy (p ! 0.05),
but not for the positive predictive value. Sensitivity and
negative predictive value were in the same range as PET.
Positron Emission Imaging, Testis Cancer Urol Int 2002;68:157–163 161
Discussion
Due to excellent cure rates in testicular cancer, the
morbidity induced by chemotherapy [22–24] and surgery
has become an important issue. Therefore, new diagnostic
methods are needed to enhance the diagnostic value for
staging and treatment control of malignant germ cell
tumors.
There are only few reports about PET using [18F]FDG
in the evaluation of germ cell cancer published so far [1, 3,
4, 6–9]. This is due to the low availability of PET scanners
and the high costs of the PET examination, that is about
1.5 times of a thoracic and abdominal CT examination. In
the present study, primary PET seemed to be more sensi-
tive, accurate and to have a higher negative predictive val-
ue compared to CT. However, this was not statistically
significant, a result comparable to the findings of Creme-
rius et al. [9]. In this relatively small group, positron imag-
ing was able to identify metastases in 3 patients in whom
CT showed no evidence of metastatic disease. Mueller-
Mattheis et al. [7] could identify 2 patients with retroperi-
toneal metastases by PET imaging in a group of 7 patients
with clinical (CT) stage I non-seminomatous germ cell
tumors; however, there was no statistical evaluation in
comparing PET and CT in their study. In contrast to those
findings, Cremerius et al. [6, 9] could not demonstrate any
significant differences between CT and primary metastat-
ic PET scans in a group of 12 and 13 patients, respec-
tively.
Statistical analysis of our findings after chemotherapy
showed no significant differences between PET and CT
values with respect to whole body detection. Similar data
were reported by Cremerius et al. [6] in a group of 13
patients who received their PET scans within the first two
weeks after the completion of chemotherapy and by
Mueller-Mattheis et al. [7] in a group of 8 patients. In con-
trast to those and to our own findings, Cremerius et al. [6]
were able to show significant differences between PET
and CT in specificity and accuracy, if PET was performed
more than 13 days after chemotherapy (n = 29). Stephens
et al. [3] considered PET to be useful for detection of
residual viable testicular carcinoma following chemother-
apy, without, however, no statistical evaluation in their
study. Nuutinen et al. [4] found that [18F]FDG imaging of
metastatic testicular cancer after chemotherapy has lim-
ited value because of a potentially high accumulation of
[18F]FDG in inflammatory tissues. Similar data were
reported by Strauss [25] for other tumor entities. None of
the authors mentioned above [4, 6, 7, 25] distinguish
between supradiaphragmatic and infradiaphragmatic le-
sions or compare statistical parameters of diagnostic val-
ue such as specificity, accuracy, etc., for positron imaging
analysis with [18F]FDG versus CT scanning.
The fact that all four false-positive findings in PET
after chemotherapy in the present study concerned supra-
diaphragmatic locations, undetectable by CT and of in-
flammatory origin, encouraged us to examine differences
between PET and CT for parameters of diagnostic value
for infra- and supradiaphragmatic lesions separately.
When PET was compared to CT with respect to infra-
diaphragmatic lesions only, PET was shown to be superi-
or in specificity, accuracy and positive predictive value.
However, statistical significance was achieved only for
specificity and accuracy (p ! 0.05) but not for positive
predictive value. Sensitivity and negative predictive value
were in the same range as CT. For supradiaphragmatic
lesions, CT was shown to be more specific, accurate and
to have a higher positive predictive value in comparison
to PET. Only values for specificity (p ! 0.05) and accuracy
(p ! 0.05) were statistically significant but not those for
the positive predictive value, although sensitivity and
negative predictive value were in the same range as PET.
These results after chemotherapy demonstrate
[18F]FDG positron imaging to be useful as a diagnostic
tool for the treatment control with respect to infradia-
phragmatic lesions. On the other hand, CT seems to be
superior compared to PET in treatment control with
respect to supradiaphragmatic lesions. One possible ex-
planation of these findings is that all false-positive lesions
were supradiaphragmatic in patients in whom the PET
scans were done within the first 10 days after the comple-
tion of chemotherapy. In this time interval after chemo-
therapy it can be assumed that patients are in a state of
relative immunodeficiency which might promote infec-
tions especially in regions exposed to an environmental
flora as that of the oropharynx and the respiratory tract.
The infradiaphragmatic space and especially the retro-
peritoneal space, excluding the gastrointestinal tract, are
not primarily in contact with a bacterial flora so that there
is probably a lower probability for infections in these
regions which might result in inflammation and thus in
false-positive PET findings.
This hypothesis might serve as a possible explanation
why [18F]FDG-PET was found to be superior to CT in
specificity and accuracy with respect to infradiaphrag-
matic lesions. Considering that the accumulation of
[18F]FDG can be enhanced by radiation therapy up to
several months following treatment [25], we must empha-
size that the present results only concern patients treated
by chemotherapy. It is also reported in the literature [25,
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26] that acute pancreatitis and hepatitis as well as any oth-
er inflammatory diseases with lymphocyte and macro-
phage accumulation may lead to false-positive results in
PET studies.
Due to our findings and those of others [4, 6, 25, 26],
we suggest that a complete physical examination is re-
quired before a PET scan is done in order to avoid false-
positive findings after chemotherapy. Also blood tests
including C-reactive protein as well as liver and pancreas
enzymes should be done at the day of PET examination.
In patients with pancytopenia in whom a low [18F]FDG
activity in tumor cells can be expected [6], and a relative
immunodeficiency exists which promotes infections, PET
studies are likely to yield false-positive results. If there are
any clinical or serological signs of inflammatory disease,
the PET scan should be postponed. The physician evalu-
ating PET scans should be aware of such clinical and sero-
logic findings. Cremerius et al. [6] suggested that the PET
scans should be done not earlier than 2 weeks after the
completion of chemotherapy, in order to avoid the false-
positive findings. We suggest to wait for a time interval of
at least 10 days after chemotherapy. However, further
investigations are necessary to define the exact time in-
terval.
Conclusions
These preliminary results demonstrate [18F]FDG posi-
tron imaging to be a useful diagnostic tool for the initial
staging and treatment control in patients with germ cell
tumors. Possible advantages compared to CT are not yet
clearly defined. Especially in patients with a positive
marker and a negative CT scan, PET may be able to iden-
tify the metastatic lesion. However, supradiaphragmatic
inflammatory processes after chemotherapy resulting in
false-positive PET findings are a disadvantage of this
method. In order to avoid false-positive findings, a close
cooperation between the physicians and those who inter-
pret the PET scan are important. Further investigations
are needed to define the time interval after chemotherapy,
which is necessary for nonspecific inflammatory changes
to subside sufficiently until PET can be expected to have a
reasonable diagnostic accuracy and specificity again.
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